Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

PepGen Inc. PEPG NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
56/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$12.50
+639.6%

PepGen Inc. (PEPG) is a Biotechnology company in the Healthcare sector, currently trading at $1.69. It has a SharesGrow Score of 55/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is PEPG = $13 (+639.6% upside).

Valuation: PEPG trades at a trailing Price-to-Earnings (P/E) of -0.8 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.36.

Net income is $90M (loss), growing at -9.3%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $17M against $147M equity (Debt-to-Equity (D/E) ratio 0.12, conservative). Current ratio is 11.94 (strong liquidity). Debt-to-assets is 9.8%. Total assets: $174M.

Analyst outlook: 5 / 6 analysts rate PEPG as buy (83%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 94/100 (Pass), Income ?/100 (Fail).

$12.50
▲ 639.64% Upside
Average Price Target
Based on 6 Wall Street analysts offering 12-month price targets for PepGen Inc., the average price target is $12.50, with a high forecast of $18.00, and a low forecast of $7.00.
Highest Price Target
$18.00
Average Price Target
$12.50
Lowest Price Target
$7.00

PEPG SharesGrow Score Overview

67/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 94/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — PEPG

✓
VALUE Pass
100/100
PEPG trades at a trailing Price-to-Earnings (P/E) of -0.8 (S&P 500 average ~25). Forward PEG 0.36 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $13, implying +669.2% from the current price $2. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
PEPG: +0%/yr revenue is, -9.3%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet PEPG: Debt-to-Equity (D/E) ratio 0.12 (conservative), Current ratio is 11.94 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
PEPG: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
94/100
Analyst outlook: 5 / 6 analysts rate PEPG as buy (83%). Analyst consensus target is $13 (+669.2% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.88-7.8
Volume1.14M
Avg Volume (30D)1.32M
Market Cap$116.8M
Beta (1Y)2.34
Share Statistics
EPS (TTM)-2.12
Shares Outstanding$42.22M
IPO Date2022-05-06
Employees79
CEOJames G. McArthur
Financial Highlights & Ratios
Gross Profit$-1.4M
EBITDA$-92.22M
Net Income$-89.66M
Operating Income$-93.61M
Total Cash$148.46M
Total Debt$17M
Net Debt$-43.51M
Total Assets$173.91M
Price / Earnings (P/E)-0.8
Analyst Forecast
1Y Price Target$12.50
Target High$18.00
Target Low$7.00
Upside+639.6%
Rating ConsensusBuy
Analysts Covering6
Buy 83% Hold 0% Sell 17%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS7133171055

Price Chart

Track all markets on TradingView
PEPG
PepGen Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
0.88 52WK RANGE 7.80

People Also View

EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.16
-2.01%
 TYRA
TYRA
Tyra Biosciences, Inc.
$35.27
-0.98%
 PHVS
PHVS
Pharvaris N.V.
$28.68
+2.87%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$27.32
+0.59%
 CGEM
CGEM
Cullinan Oncology, Inc.
$14.35
+0.70%
 CMPX
CMPX
Compass Therapeutics, Inc.
$5.44
+4.62%
 TRDA
TRDA
Entrada Therapeutics, Inc.
$14.03
+1.01%
 PRTC
PRTC
PureTech Health plc
$17.87
+0.37%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message